Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific share transaction and does not contain financial statements or performance metrics.
Material Changes
The filing reports a change in shareholding interests for Dr P J T Vallance, a Person Discharging Managerial Responsibilities. Specifically, Dr S Dexter, a Connected Person of Dr Vallance, acquired 291 GSK Ordinary Shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on the disclosure of the share acquisition.
Important Facts for Investors
- Transaction Date: The acquisition occurred following the dividend reinvestment on July 9, 2015, with notification to GSK on July 27, 2015.
- Share Count: 291 Ordinary Shares were acquired.
- Price: The acquisition price was 1372.05 pence per Share.
- Context: The purchase resulted from the re-investment of the dividend paid to shareholders.